TX-HEARTSCIENCES
HeartSciences , an innovative medical device company, is proud to announce its participation as an exhibitor at the upcoming 2018 International Congress on Electrocardiology (ICE ), which will be held in Makuhari Messe, Chiba City, Japan, June 28-30, 2018. ICE2018 will be the joint meeting of the 45th Congress of the International Society of Electrocardiology (ISE) and the 18th Congress of the International Society for Holter and Noninvasive Electrocardiology (ISHNE ). This Congress will focus on Electrocardiography, from noninvasive diagnosis to prognosis covering basic electrophysiology, novel signal processing methods of Holter ECG, prognostic ECG techniques for preventing sudden cardiac death, applications of antiarrhythmic agents and direct oral anticoagulants, a critical role of catheter ablation for tachyarrhythmias and appropriate use of implantable devices.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180625005026/en/
About HeartSciences
HeartSciences is leading innovation in the field of electrocardiography through the application of continuous wavelet transform (CWT) signal processing and artificial intelligence. Wavelet signal processing is currently used in many different industries as an important tool to provide insights and new valuable data related to spectral analysis of a signal. HeartSciences’ MyoVista® Wavelet ECG (wav ECG™) is a first-to-market 12-lead resting electrocardiograph with new informatics based on wavelet signal processing. Patented informatics focus on energy related information rather than conventional voltage-based information. HeartSciences mission is to enable accurate, affordable screening for the early detection of heart disease.
In addition to proprietary informatics, the MyoVista wav ECG Device has full 12-lead resting ECG capabilities including analysis using the Glasgow Algorithm, one of the world’s most respected interpretive algorithms. The device has a 15.6-inch high-resolution touchscreen display and incorporates many features commonly associated with a tablet device requiring minimal user training with no change in ECG clinical workflow. The MyoVista wav ECG Device is not currently FDA approved for commercial sale or distribution in the United States.
HeartSciences is a privately-held U.S. corporation based in Southlake, Texas.
For more information visit www.heartsciences.com .
Media
The following link leads to a multimedia support platform designed to
provide rapid download of media elements needed to develop your story
about HeartSciences and MyoVista Technology.
https://digitalmedia.vnr1.com/2018/06/20/heartsciences/
View source version on businesswire.com: https://www.businesswire.com/news/home/20180625005026/en/
Contact:
HeartSciences
Gene Gephart, +1-737-346-1089
gene.gephart@heartsciences.com
or
Investor
Contact
Zimmons International Communications
Jennifer K.
Zimmons, +1-917-214-3514
jzimmons@zimmonsic.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
AZ-BLUE-YONDER29.3.2024 13:14:28 CET | Press release
Blue Yonder Announces Binding Agreement To Acquire One Network Enterprises for Approximately $839 Million To Create Multi-Enterprise Supply Chain Ecosystem
DEWA29.3.2024 13:13:28 CET | Press release
Dubai Electricity and Water Authority PJSC Shareholders Approve Payment of AED 3.1 Billion in Dividends
LIBERTEX29.3.2024 06:26:33 CET | Press release
PAN Finance Names Libertex ‘Global CFD Broker of the Year’
MIDEA-GROUP29.3.2024 02:40:30 CET | Press release
Midea Group releases its first-ever ESG brand story with an unexpected VIP visit highlighting its commitment to sustainability.
NY-DC-ADMINISTRATION28.3.2024 21:15:26 CET | Press release
DC Secretary Announces Annual Determinations Committees Outcome
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom